Pulmatrix (NASDAQ:PULM – Get Free Report) is projected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Pulmatrix to post earnings of ($2.00) per share and revenue of $1.53 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 9:30 AM ET.
Pulmatrix (NASDAQ:PULM – Get Free Report) last released its earnings results on Thursday, August 13th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($2.00) by $1.71.
Pulmatrix Stock Up 0.7%
PULM stock opened at $1.50 on Thursday. Pulmatrix has a twelve month low of $1.16 and a twelve month high of $4.99. The company has a market cap of $5.47 million, a PE ratio of -1.36 and a beta of 1.93. The business’s 50-day simple moving average is $1.49 and its 200 day simple moving average is $1.73.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings cut Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Pulmatrix presently has an average rating of “Sell”.
View Our Latest Stock Report on Pulmatrix
About Pulmatrix
Pulmatrix, Inc is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory and other diseases. The company’s research is based on its iSPERSE dry-powder delivery technology, which is designed to enable efficient administration of pharmaceutical compounds directly to the lungs.
Pulmatrix’s pipeline has included PUR1900, an inhaled formulation of itraconazole being developed for respiratory fungal infections, including allergic bronchopulmonary aspergillosis.
Featured Stories
- Five stocks we like better than Pulmatrix
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
